IC conference calls

Discussion in 'Lundbeck' started by anonymous, Oct 27, 2017 at 9:02 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Thoughts behind changes???
     

  2. anonymous

    anonymous Guest

    yes let's pole the real sales force
     
  3. anonymous

    anonymous Guest

    First of all, it was 30 min of saying the same damn thing over and over again. They could have just sent out a 1-pager explaining it instead of wasting 30 min of time saying the same thing 30 different ways. But they probably wanted us to “feel” like we had some say, which of course we didn’t.

    In my opinion it sounds to me like their goal is to reward top talent in an attempt to keep people who view themselves as such. They contradicted themselves when they said it’s uncapped atvthe top and uncalled at the bottom. Originally they were saying $2500 floor and $22000 ceiling. Then they made it sound like you could make more than $22000/trimester and less than $2500/trimester.
     
  4. anonymous

    anonymous Guest

    They sill don't get it. The bonus could be $50,000 each trimester, but if goal is ridiculous, what does it matter what the possible payout is! Study after study will tell you that employees say money is important, but work environment (which is makeup of many factors) is more important. Unlike Alpha, the Gamma/Beta team deals in a 99% generic market place where the strategy is to take share from generics! How damn unrealistic is that! Then you have ASM's with just a handful of reps wanting to ride with you every time you turn around, and the most of them have no clue about pharmaceutical sales! All they believe in is showing the patient profile even though 2 Otsuka reps and a Takeda rep doing the same damn thing that week, and a call is not a call unless you use that stupid vis aid on the iPad, or a hardcopy!

    Back to what makes people want to stay at a company, the most important reason is their immediate manager. In our region, I know of only one ASM that is truly liked and respected. One! In talking with other people from other regions, I have yet to meet one person that likes/respects their manager.

    Then there is the matter of job security, which is probably #2 on the list of why people want to stay at a company. People, we have no pipeline, and everyone knows. The future indications for Rex are a long shot at best. The infamous 35700 is drifting somewhere out there, and nobody ever hears about ti. That's all we got! Are you will to gamble to next few years that something is going to pop out somewhere from R&D and save the day? I've got 10 to 15 years left, and I can tell you I am not willing to take the risk. Then, add in what the next CEO has up their sleeve to increase profits, and like Kare, he might come in swinging a big ax!

    Hang on tight! 2018 will likely be a bumpy ride!
     
  5. anonymous

    anonymous Guest

    It really doesn't matter what they say. They'll increase goals out of reach for all sales forces and no one will attain lofty goals.
     
  6. anonymous

    anonymous Guest

    the call was a complete waste of time! People will leave with this new IC plan and that's what they want. What's the point of taking a survey at this company anymore they don't listen.
     
  7. anonymous

    anonymous Guest

    Excellent post and right on the money! This post says it ll. They just don't get it, and never will.
     
  8. anonymous

    anonymous Guest

    Most people are quitting in neuro because they are fed up with the company jacking up the price of northera and its now absurd that it costs around 165,000 dollars a year now at max dose. Most reps have found that the pay for the effort isn't even close. The new segmentation thinks we can ask for first line business in some customer types. No common sense here at Lundbeck.

    There will be hiring for other companies in 2018 and this company will witness another 25% attrition rate with more deer in the headlights from the managers who don't get it. The cost of lost experience, time in selling products in vacant areas is going to cost this company millions for being short sighted on making things right. Meanwhile keep telling us about how much profit you are making. At least the investors and Danish employees appreciate the US healthcare system funding their retirements.
     
  9. anonymous

    anonymous Guest

    I agree with your sentiment but your cost $ are a bit off.
     
  10. anonymous

    anonymous Guest

    its 13,600 dollars a month for 300mg capsules for qty 180 (30 day supply). Check your sources and why patients are bringing into their doctor office showing them how expensive it is. Regardless if they pay for the drug, the insurance companies are making our prescribers aware why this is the last line drug. Any foundation support we have for 3000 or so patients at this cost wasn't covering anything we were giving to help offset the cost of the medicine. That's why we are just maximizing profits for those in Denmark who would never allow this to happen to their own healthcare members in their country.